Quince Therapeutics Inc. (formerly Novosteo Inc.) has presented data on NOV-004, a construct that delivers abaloparatide therapeutic agent into the fracture site, designed for the treatment of osteogenesis imperfecta.
Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented preclinical data for BI-456906, a novel long-acting glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, currently in phase II development in patients with obesity and nonalcoholic steatohepatitis (NASH).
Researchers from Roche Holding AG disclosed the discovery and preclinical evaluation data for RG-7774 (vicasinabin), a novel cannabinoid CB2 receptor (CB2R) agonist being developed for the treatment of diabetic retinopathy (DR).
Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise.
Pulmonary hypertension (PH) is characterized by persistent increases of pulmonary arterial pressure that can lead in the long term to right ventricular failure.
The interaction of immune checkpoints, such as programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4), with their ligands leads to T-cell deactivation, allowing cancer cells to escape from the immune system.
H-Cyte Inc. has completed its acquisition of Jantibody, a novel cancer immunotherapeutic agent that has demonstrated promising efficacy in controlling ovarian cancer and mesothelioma in preclinical models.
RSS
